托吡酯治疗伴代谢综合征的隐源性感觉性周围神经病的安全性与疗效:TopCSPN随机临床试验
TopCSPN为双盲、安慰剂对照随机临床试验,在20个中心纳入132例伴代谢综合征的隐源性感觉性周围神经病患者,随机接受托吡酯(最大耐受剂量100 mg/日)或安慰剂。意向治疗分析中,表皮内神经纤维密度(IENFD)年变化差为0.21纤维/mm(95%CI -0.43至∞),Norfolk生活质量-糖尿病神经病变(NQOL-DN)评分年变化差为-1.52分(95%CI -∞至1.19),均为非劣效但未达优效;符合方案分析中NQOL-DN评分显示优效(-3.69分/年;95%CI -∞至-0.73)。结论认为托吡酯在主要意向治疗分析中未减缓IENFD下降或影响NQOL-DN评分,部分参与者对托吡酯不耐受。
要点
- 意向治疗分析中托吡酯对IENFD和NQOL-DN评分均为非劣效但未达优效。
- 符合方案分析中NQOL-DN评分显示优效(-3.69分/年;95%CI -∞至-0.73)。
- 部分参与者对托吡酯不耐受。
核心结论
- 意向治疗分析中托吡酯未减缓IENFD下降或影响NQOL-DN评分。
- 部分参与者对托吡酯不耐受。
- 在基于血清水平判定为依从且无重大方案偏离的参与者中,NQOL-DN评分显示优效。
研究设计与样本
- TopCSPN为双盲、安慰剂对照随机临床试验,2018年2月至2021年10月在20个中心开展。
- 共筛查211人,132人随机分组:托吡酯组66人,安慰剂组66人。
- 纳入18至80岁伴代谢综合征的隐源性感觉性周围神经病患者,按体重指数(<30 vs ≥30)随机分组。
主要发现
- 托吡酯组平均(SD)年龄61(10)岁,男性38人(58%);安慰剂组平均(SD)年龄62(11)岁,男性44人(67%)。
- 意向治疗分析中IENFD年变化差为0.21纤维/mm(95%CI -0.43至∞),NQOL-DN评分年变化差为-1.52分(95%CI -∞至1.19),均为非劣效但未达优效。
- 符合方案分析中NQOL-DN评分年变化差为-3.69分(95%CI -∞至-0.73),显示优效。
- 托吡酯组相对安慰剂的IENFD平均(SD)年变化为0.56纤维/mm(95%CI -0.21至∞)。
- 托吡酯组IENFD保持稳定,而安慰剂组下降与预期自然病史一致,但该差异未显示优效。
局限性
- 部分参与者对托吡酯不耐受。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cryptogenic sensory peripheral neuropathy (CSPN) is highly prevalent and often disabling due to neuropathic pain. Metabolic syndrome and its components increase neuropathy risk. Diet and exercise have shown promise but are limited by poor adherence. OBJECTIVE: To determine whether topiramate can slow decline in intraepidermal nerve fiber density (IENFD) and/or neuropathy-specific quality of life measured using the Norfolk Quality of Life-Diabetic Neuropathy (NQOL-DN) scale. DESIGN, SETTING, AND PARTICIPANTS: Topiramate as a Disease-Modifying Therapy for CSPN (TopCSPN) was a double-blind, placebo-controlled, randomized clinical trial conducted between February 2018 and October 2021. TopCSPN was performed at 20 sites in the National Institutes of Health-funded Network for Excellence in Neurosciences Clinical Trials (NeuroNEXT). Individuals with CSPN and metabolic syndrome aged 18 to 80 years were screened and randomly assigned by body mass index (<30 vs ≥30), which is calculated as weight in kilograms divided by height in meters squared. Patients were excluded if they had poorly controlled diabetes, prior topiramate treatment, recurrent nephrolithiasis, type 1 diabetes, use of insulin within 3 months before screening, history of foot ulceration, planned bariatric surgery, history of alcohol or drug overuse in the 2 years before screening, family history of a hereditary neuropathy, or an alternative neuropathy cause. INTERVENTIONS: Participants received topiramate or matched placebo titrated to a maximum-tolerated dose of 100 mg per day. MAIN OUTCOMES AND MEASURES: IENFD and NQOL-DN score were co-primary outcome measures. A positive study was defined as efficacy in both or efficacy in one and noninferiority in the other. RESULTS: A total of 211 individuals were screened, and 132 were randomly assigned to treatment groups: 66 in the topiramate group and 66 in the placebo group. Age and sex were similar between groups (topiramate: mean [SD] age, 61 (10) years; 38 male [58%]; placebo: mean [SD] age, 62 (11) years; 44 male [67%]). The difference in change in IENFD and NQOL-DN score was noninferior but not superior in the intention-to-treat (ITT) analysis (IENFD, 0.21 fibers/mm per year; 95% CI, -0.43 to ∞ fibers/mm per year and NQOL-DN score, -1.52 points per year; 95% CI, -∞ to 1.19 points per year). A per-protocol analysis excluding noncompliant participants based on serum topiramate levels and those with major protocol deviations demonstrated superiority in NQOL-DN score (-3.69 points per year; 95% CI, -∞ to -0.73 points per year). Patients treated with topiramate had a mean (SD) annual change in IENFD of 0.56 fibers/mm per year relative to placebo (95% CI, -0.21 to ∞ fibers/mm per year). Although IENFD was stable in the topiramate group compared with a decline consistent with expected natural history, this difference did not demonstrate superiority. CONCLUSION AND RELEVANCE: Topiramate did not slow IENFD decline or affect NQOL-DN score in the primary ITT analysis. Some participants were intolerant of topiramate. NQOL-DN score was superior among those compliant based on serum levels and without major protocol deviations. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02878798.
引用
- Smith AG, Singleton JR, Aperghis A, et al. Safety and Efficacy of Topiramate in Individuals With Cryptogenic Sensory Peripheral Neuropathy With Metabolic Syndrome: The TopCSPN Randomized Clinical Trial. JAMA Neurol. 2023. PMID: 37870862. doi:10.1001/jamaneurol.2023.3711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。